Pharmaceutical compound
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | DNA |
| Clinical data | |
| Other names | GX-19N |
| Routes of administration | Intramuscular |
| Identifiers | |
| DrugBank | |
.svg){kind=small}
GX-19 is a COVID-19 vaccine candidate developed by Genexine consortium.
It is a DNA-based vaccine that encodes the SARS-CoV-2 spike protein.
References
- "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. United States National Library of Medicine. 24 June 2020. NCT04445389. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- "Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults". clinicaltrials.gov. United States National Library of Medicine. 18 January 2021. Retrieved 16 March 2021.
- "S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
- "Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea". 11 June 2020. Retrieved 1 August 2020.
- Seo YB, Suh YS, Ryu JI, Jang H, Oh H, Koo BS, et al. (March 2021). "Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates". Vaccines. 9 (4): 307. doi:10.3390/vaccines9040307. PMC 8063950. PMID 33804981.
| Artificial induction of immunity / Immunization: Vaccines, Vaccination, Infection, Inoculation (J07) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Development | |||||||||||
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Misplaced Pages by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Misplaced Pages by expanding it. |